Xiang Shao

US Patent:

20040161817, Aug 19, 2004

Filed:

Jun 4, 2002

Appl. No.:

10/163863

Inventors:

Trish Benton - Moss Beach CA, US
Christopher Bebbington - San Mateo CA, US
Karla Henning - Burlingame CA, US
David King - Belmont CA, US
Robert Crombie - Barbridge, GB
Xiang Shao - Santa Clara CA, US

Assignee:

Corixa Corporation - Seattle WA

International Classification:

C12P021/02
C12N005/06
C12N015/85

US Classification:

435/069100, 435/455000, 435/325000

Abstract:

Compositions and methods for the high-level, large-scale production of recombinant proteins are disclosed. Illustrative compositions comprise one or more expression vectors capable of high-level protein and/or polypeptide expression in combination with an immortalized host cell-line capable of growth in serum-free, suspension culture. Bi-directional UCOE vectors that permit the simultaneous, high-level expression of two or more recombinant proteins and/or polypeptides from a single UCOE based plasmid vector.

US Patent:

20220204618, Jun 30, 2022

Filed:

Feb 11, 2022

Appl. No.:

17/670398

Inventors:

- Princeton NJ, US
Alan J. Korman - Piedmont CA, US
Shrikant Deshpande - Fremont CA, US
Amy D. Jhatakia - Fremont CA, US
Richard Y. Huang - Bridgewater NJ, US
Guodong Chen - East Brunswick NJ, US
Ginger C. Rakestraw - Somerville MA, US
Karla Ann Henning - Milpitas CA, US
Vangipuram S. Rangan - Pleasant Hill CA, US
Christine Bee - San Francisco CA, US
Xiang Shao - Los Altos CA, US

International Classification:

C07K 16/28
A61K 39/395
A61P 35/00

Abstract:

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

US Patent:

20220195042, Jun 23, 2022

Filed:

Feb 10, 2022

Appl. No.:

17/668807

Inventors:

- Princeton NJ, US
Alan J. Korman - Piedmont CA, US
Shrikan Deshpande - Fremont CA, US
Amy D. Jhatakia - Fremon CA, US
Richard Y. Huang - Bridgewater NJ, US
Guodong Chen - East Brunswick NJ, US
Ginger G. Rakestraw - Somerville MA, US
Karla Ann Henning - Milpitas CA, US
Vangipuram S. Rangan - Pleasant Hill CA, US
Christine Bee - San Francisco CA, US
Xiang Shao - Los Altos CA, US

International Classification:

C07K 16/28
C07K 1/22
C12N 5/071
C12N 15/85
C12P 21/00

Abstract:

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

US Patent:

20200399385, Dec 24, 2020

Filed:

Apr 13, 2020

Appl. No.:

16/847130

Inventors:

- Princeton NJ, US
Indrani CHAKRABORTY - Fremont CA, US
Marie-Michelle Navarro GARCIA - San Jose CA, US
Thomas D. KEMPE - Sunnyvale CA, US
Alan J. KORMAN - Piedmont CA, US
Alexander T. KOZHICH - Princeton NJ, US
Hadia LEMAR - Tracy CA, US
Mark MAURER - Seattle WA, US
Christina Maria MILBURN - Santa Cruz CA, US
Michael QUIGLEY - Ambler PA, US
Xiang SHAO - Milpitas CA, US
Mohan SRINIVASAN - Cupertino CA, US
Kent THUDIUM - Oakland CA, US
Susan Chien-Szu WONG - Fremont CA, US
Jochem GOKEMEIJER - Wayland MA, US
Xi-Tao WANG - Wellesley MA, US
Han CHANG - West Windsor NJ, US
Patrick GUIRNALDA - Framingham MA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
C07K 16/30
A61P 35/00
A61K 39/395
G01N 33/574

Abstract:

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

US Patent:

20200277612, Sep 3, 2020

Filed:

Oct 2, 2018

Appl. No.:

16/753102

Inventors:

- Princeton NJ, US
Xiang SHAO - Milpitas CA, US

International Classification:

C12N 15/63
C07K 16/00
G01N 33/53

Abstract:

Described herein are vectors and methods that are useful for screening variable region sequences of antigen binding molecules with high efficiency. Such vectors rely on the native translation initiation sequences of the variable regions to drive the expression of both the variable region and a reporter gene in the vector.

US Patent:

20200199226, Jun 25, 2020

Filed:

Nov 14, 2019

Appl. No.:

16/683927

Inventors:

- Princeton NJ, US
Alan J. Korman - Piedmont CA, US
Shrikant Deshpande - Fremont CA, US
Amy D. Jhatakia - Fremont CA, US
Richard Y. Huang - Bridgewater NJ, US
Guodong Chen - East Brunswick NJ, US
Ginger C. Rakestraw - Somerville MA, US
Karla Ann Henning - Milpitas CA, US
Vangipuram S. Rangan - Pleasant Hill CA, US
Christine Bee - San Francisco CA, US
Xiang Shao - Milpitas CA, US

International Classification:

C07K 16/28
A61K 47/68
A61K 39/395
G01N 33/68
A61P 35/00

Abstract:

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

US Patent:

20180362619, Dec 20, 2018

Filed:

Dec 20, 2016

Appl. No.:

16/061646

Inventors:

- Princeton NJ, US
Henrik ANDERSEN - Seattle WA, US
Xiang SHAO - Milpitas CA, US
Arvind RAJPAL - San Francisco CA, US

Assignee:

BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ

International Classification:

C07K 16/08
A61K 47/68
C07K 16/28
C07K 16/30
A61P 35/00

Abstract:

Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine.

US Patent:

20180237534, Aug 23, 2018

Filed:

May 26, 2016

Appl. No.:

15/577375

Inventors:

- Princeton NJ, US
Indrani CHAKRABORTY - Fremont CA, US
Marie-Michelle Navarro GARCIA - San Jose CA, US
Thomas D. KEMPE - Sunnyvale CA, US
Alan J. KORMAN - Piedmont CA, US
Alexander T. KOZHICH - Princeton NJ, US
Hadia LEMAR - Tracy CA, US
Mark MAURER - Seattle WA, US
Christina Maria MILBURN - Santa Cruz CA, US
Michael QUIGLEY - Ambler PA, US
Maria RODRIGUEZ - San Jose CA, US
Xiang SHAO - Milpitas CA, US
Mohan SRINIVASAN - Cupertino CA, US
Brenda L. STEVENS - Seattle WA, US
Kent THUDIUM - Oakland CA, US
Susan Chien-Szu WONG - Fremont CA, US
Jochem GOKEMEIJER - Wayland MA, US
Xi-Tao WANG - Wellesley MA, US
Han CHANG - West Windsor NJ, US
Christine HUANG - Princeton NJ, US
Zheng YANG - Plainsboro NJ, US
Yan FENG - Pittsburgh PA, US
Patrick GUIRNALDA - Framingham MA, US
Nils LONBERG - Woodside CA, US
Bryan C. BARNHART - Philadelphia PA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Karla A. HENNING - Milpitas CA, US
Michelle Minhua HAN - Piedmont CA, US
Ming LEI - Princeton NJ, US
Liang SCHWEIZER - Shanghai PR, CN
Sandra V. HATCHER - Hillsborough NJ, US
Arvind RAJPAL - San Francisco CA, US
Mark J. SELBY - San Francisco CA, US

International Classification:

C07K 16/28
C07K 16/30
A61K 39/395
G01N 33/574
A61P 35/00

Abstract:

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.